MED Stock Chart & Stats
$180.00
$0.00(0.00%)
At close: 4:00 PM EDT
$180.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$175.00 - $370.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$1.90B
Enterprise Value-$40.69
Total Cash (Recent Filing)$168.95M
Total Debt (Recent Filing)$16.10M
Price to Earnings (P/E)―
Beta0.15
Next Earnings
Aug 03, 2026EPS Estimate
-11.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.82
Shares Outstanding11,119,115
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.59
Price to Sales (P/S)0.30
P/FCF Ratio93.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Medifast News
MED FAQ
What was Medifast Inc’s price range in the past 12 months?
Medifast Inc lowest stock price was $175.00 and its highest was $370.00 in the past 12 months.
What is Medifast Inc’s market cap?
Medifast Inc’s market cap is $1.90B.
When is Medifast Inc’s upcoming earnings report date?
Medifast Inc’s upcoming earnings report date is Aug 03, 2026 which is tomorrow.
How were Medifast Inc’s earnings last quarter?
Medifast Inc released its earnings results on May 04, 2026. The company reported -$3.296 earnings per share for the quarter, beating the consensus estimate of -$9.021 by $5.725.
Is Medifast Inc overvalued?
According to Wall Street analysts Medifast Inc’s price is currently Overvalued.
Does Medifast Inc pay dividends?
Medifast Inc does not currently pay dividends.
What is Medifast Inc’s EPS estimate?
Medifast Inc’s EPS estimate is -11.28.
How many shares outstanding does Medifast Inc have?
Medifast Inc has 11,119,115 shares outstanding.
What happened to Medifast Inc’s price movement after its last earnings report?
Medifast Inc reported an EPS of -$3.296 in its last earnings report, beating expectations of -$9.021. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Medifast Inc?
Currently, no hedge funds are holding shares in MX:MED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medifast Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
MX:MED Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.71%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.99%
Trailing 12-Months
Company Description
Medifast Inc
Medifast, Inc., through its various divisions, develops and provides a range of consumable health and nutritional items tailored for weight loss, weight management, and general wellness. These products are distributed across the United States and the Asia-Pacific region. Their extensive portfolio encompasses snack bars, savory bites, cereals, drinks, substantial meal choices, oatmeal, pancakes, puddings, soft serves, shakes, smoothies, baked goods, and soups. These offerings are marketed under proprietary brands like OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home. The company facilitates sales primarily through direct e-commerce transactions. Established in 1980, Medifast, Inc. maintains its corporate headquarters in Baltimore, Maryland.
MED Company Deck
MED Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced clear early operational and scientific progress — notably improving coach productivity, sequential revenue stabilization, a strong cash position, cost-savings initiatives, and a defined metabolic-health product roadmap — against substantial near-term financial headwinds, including a 34% YoY revenue decline, a roughly 45% drop in active earning coaches, compressed gross margins, and continued net losses. Management is optimistic about trajectory and expects profitability improvements beginning in Q4 2026 contingent on execution and the new product rollout, but material risks remain.View all MX:MED earnings summaries